Sexual organ-sparing with hydrogel spacer injections for rectal cancer radiotherapy: a feasibility pilot study
Abstract
Objectives:
The aim of this pilot study was to investigate in two rectal cancer patients undergoing neoadjuvant chemo-radiotherapy (nCRT) the implant feasibility and dosimetric benefit in sexual organ-sparing of an injectable, absorbable, radiopaque hydrogel spacer.
Methods:
Two rectal cancer patients (one male and one female) underwent hydrogel implant between rectum and vagina/prostate before nCRT and curative surgery. A CT scan was performed before and after injection and a comparative dosimetric study was performed testing a standard (45/50 Gy) and a dose escalated (46/55.2 Gy) schedule.
Results:
In both patients, the spacer implant in the recto-prostatic or recto-vaginal space was feasible and well tolerated. For the male, the dosimetric benefit with spacer was minimal for sexual organs. For the female however, doses delivered to the vagina were significantly reduced with spacer with a mean reduction of more than 5 Gy for both regimens.
Conclusions:
For organ preservation protocols and selected sexually active female patients, use of hydrogel spacers can be considered to spare sexual organs from the high radiotherapy dose levels.
Advances in knowledge:
For females with advanced rectal tumor, a spacer implant between the rectum and the vagina before nCRT is feasible and reduces doses delivered to the vagina.
REFERENCES
1. . Pre-Operative chemoradiation for non-metastatic locally advanced rectal cancer. Cochrane Database Syst Rev 2012; 12: CD008368. doi: https://doi.org/10.1002/14651858.CD008368.pub2 http://www.ncbi.nlm.nih.gov/pubmed/23235660
2. . Impact of short-term preoperative radiotherapy on health-related quality of life and sexual functioning in primary rectal cancer: report of a multicenter randomized trial. J Clin Oncol 2005; 23: 1847–58. doi: https://doi.org/10.1200/JCO.2005.05.256 http://www.ncbi.nlm.nih.gov/pubmed/15774778
3. . Dosimetric predictors of radiation-induced vaginal stenosis after pelvic radiation therapy for rectal and anal cancer. Int J Radiat Oncol Biol Phys 2015; 92: 548–54. doi: https://doi.org/10.1016/j.ijrobp.2015.02.029 http://www.ncbi.nlm.nih.gov/pubmed/25936810
4. . Erectile dysfunction and absorbed dose to penile base structures in a randomized trial comparing Ultrahypofractionated and conventionally fractionated radiation therapy for prostate cancer. Int J Radiat Oncol Biol Phys 2020; 107: 143–51. doi: https://doi.org/10.1016/j.ijrobp.2020.01.022 http://www.ncbi.nlm.nih.gov/pubmed/32004582
5. . Optimization of radiation therapy techniques for prostate cancer with prostate-rectum spacers: a systematic review. Int J Radiat Oncol Biol Phys 2014; 90: 278–88. doi: https://doi.org/10.1016/j.ijrobp.2014.06.044 http://www.ncbi.nlm.nih.gov/pubmed/25304788
6. . Hydrogel spacer prospective multicenter randomized controlled pivotal trial: dosimetric and clinical effects of perirectal spacer application in men undergoing prostate image guided intensity modulated radiation therapy. Int J Radiat Oncol Biol Phys 2015; 92: 971–7. doi: https://doi.org/10.1016/j.ijrobp.2015.04.030 http://www.ncbi.nlm.nih.gov/pubmed/26054865
7. . Sexual quality of life following prostate intensity modulated radiation therapy (IMRT) with a rectal/prostate spacer: secondary analysis of a phase 3 trial. Pract Radiat Oncol 2018; 8: e7–15. doi: https://doi.org/10.1016/j.prro.2017.07.008 http://www.ncbi.nlm.nih.gov/pubmed/28951089
8. . Pelvic normal tissue contouring guidelines for radiation therapy: a radiation therapy Oncology Group consensus panel atlas. Int J Radiat Oncol Biol Phys 2012; 83: e353–62. doi: https://doi.org/10.1016/j.ijrobp.2012.01.023 http://www.ncbi.nlm.nih.gov/pubmed/22483697
9. . Elective clinical target volumes for conformal therapy in anorectal cancer: a radiation therapy Oncology Group consensus panel contouring atlas. Int J Radiat Oncol Biol Phys 2009; 74: 824–30. doi: https://doi.org/10.1016/j.ijrobp.2008.08.070 http://www.ncbi.nlm.nih.gov/pubmed/19117696
10. . Use of normal tissue complication probability models in the clinic. Int J Radiat Oncol Biol Phys 2010; 76(3 Suppl): S10–19. doi: https://doi.org/10.1016/j.ijrobp.2009.07.1754 http://www.ncbi.nlm.nih.gov/pubmed/20171502
11. . Phase II study of preoperative helical tomotherapy with a simultaneous integrated boost for rectal cancer. Int J Radiat Oncol Biol Phys 2012; 83: 142–8. doi: https://doi.org/10.1016/j.ijrobp.2011.05.068 http://www.ncbi.nlm.nih.gov/pubmed/22014952
12. . Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma. clinicopathologic correlations. Cancer 1994; 73: 2680–6. doi: https://doi.org/10.1002/1097-0142(19940601)73:11<2680::aid-cncr2820731105>3.0.co;2-c http://www.ncbi.nlm.nih.gov/pubmed/8194005
13. . Impact of dose to the bladder trigone on long-term urinary function after high-dose intensity modulated radiation therapy for localized prostate cancer. Int J Radiat Oncol Biol Phys 2014; 88: 339–44. doi: https://doi.org/10.1016/j.ijrobp.2013.10.042 http://www.ncbi.nlm.nih.gov/pubmed/24411606
14. . Analysis of motion of the rectum during preoperative intensity modulated radiation therapy for rectal cancer using cone-beam computed tomography. Radiat Oncol 2015; 10: 2. doi: https://doi.org/10.1186/s13014-014-0311-6 http://www.ncbi.nlm.nih.gov/pubmed/25566869
15. . Impact of hydrogel spacer injections on interfraction prostate motion during prostate cancer radiotherapy. Acta Oncol 2016; 55: 834–8. doi: https://doi.org/10.3109/0284186X.2015.1128118 http://www.ncbi.nlm.nih.gov/pubmed/26796870
